Anaeropharma will present new research outcomes at AACR Conference on Tumor Immunology and Immunotherapy

At upcoming AACR Special Conference on Tumor Immunology and Immunotherapy taking place October 20-23, 2016 in Boston, MA, Anaeropharma will present its new research outcomes regarding cancer immunotherapy titled “Anti-CTLA-4 antibody scFv producing recombinant Bifidobacterium secretes CTLA-4 blocker specifically inside hypoxic tumor and suppresses tumor growth in syngeneic mice model”.

PDF download here

Comments are closed.